CLINICAL STUDY

Polymorphism of the polyalanine tract of thyroid transcription factor-2 gene in patients with thyroid dysgenesis

Akira Hishinuma, Yoshihide Ohyama³, Takeo Kuribayashi¹, Narumi Nagakubo⁴, Takashi Namatame², Keiko Shibayama³, Osamu Arisaka¹, Nobuo Matsuura³ and Tamio Ieiri

Department of Clinical Laboratory Medicine, ¹Department of Pediatrics, ²Institute for Medical Sciences, Dokkyo University School of Medicine, Mibu, Tochigi 321-0293, Japan, ³Department of Pediatrics, Kitasato University School of Medicine, Sagami-hara, Kanagawa 228-8555, Japan and ⁴Sumikin Bioscience Inc., Tokyo 100-0004, Japan

(Correspondence should be addressed to Akira Hishinuma; Email: a-hishi@dokkyomed.ac.jp)

Abstract

Objective: One of the thyroid-specific transcription factors, thyroid transcription factor-2 (TTF-2), performs a crucial role in the development of the thyroid gland. We performed genetic analysis of the *TTF2* gene (encoding TTF-2) in patients with thyroid dysgenesis.

Methods: By direct sequencing of the PCR products of *TTF2*, we screened the genomic DNA from 46 patients with thyroid dysgenesis (five had agenesis, six had hypoplasia, 15 had ectopy, and 20 were undetermined). We also studied the transcriptional activities of *TTF2* by co-expressing the luciferase gene directed by the human thyroglobulin gene promoter.

Results: Human *TTF2* consists of a forkhead domain, a polyalanine tract, and unique C-terminal residues. In one of the patients with an ectopic sublingual thyroid, we found a polyalanine tract of 11 alanine residues on one chromosome instead of the 14 alanine residues found in normal controls. In one patient with hypoplasia, the polyalanine tract consisted of 12 heterozygous alanine residues. The reduced polyalanine tracts were not detected in 101 normal individuals. However, the expression study showed that the transcriptional activities of *TTF2* with reduced polyalanine-tract lengths were equal to that of *TTF2* with an unreduced polyalanine tract.

Conclusion: These results suggest that the polymorphism of the polyalanine tract of *TTF2* is not a frequent cause of developmental defects of the human thyroid gland.

European Journal of Endocrinology 143 385–389

Introduction

Thyroid transcription factor-2 (TTF-2) was initially identified to regulate expression of the thyroid-specific genes, thyroglobulin and thyroperoxidase, co-ordinately with thyroid transcription factor-1 (TTF-1) and paired box homeotic gene 8 (*PAX8*) (1). TTF-2 is temporally expressed in the developing thyroid, which is consistent with a role in control of the morphogenesis of the thyroid gland (2). *TTF2*-null mutant mice exhibited either a sublingual or a completely absent thyroid gland as well as a cleft palate (3). Cloning of the human *TTF2* gene showed that human *TTF2* was identical to forkhead transcription factor FKHK15 (4).

Thyroid dysgenesis is the main cause of congenital primary hypothyroidism, which affects 1 in 4000 newborns. Developmental defects of the thyroid gland range from agenesis and ectopy to hypoplasia. In most cases of thyroid dysgenesis, genetic abnormalities are unknown, although a few cases, caused by mutations of the thyrotropin receptor (5–7) and *PAX8* (8), or

deletion of *TTF1* (encoding TTF-1) (9, 10), have been reported. Only one case of thyroid dysgenesis associated with a cleft palate and choanal atresia was caused by a missense mutation of *TTF2* (11).

In this work, we studied *TTF2* in patients with thyroid dysgenesis. *TTF2* consists of a single exon that codes for a forkhead domain, a polyalanine tract, and unique C-terminal residues. Initially, the polyalanine tract was reported to consist of 19 residues (4). Subsequently, the length of the major alanine stretch was shown to be 14 residues (12). We detected reduced polyalanine residues in two patients with thyroid dysgenesis, and we performed a functional analysis.

Materials and methods

TTF2 gene analysis

Genomic DNA was isolated from 200 µl peripheral blood, obtained from each of 46 patients with thyroid dysgenesis (five with agenesis, six with hypoplasia, 15 with ectopy, and 20 that were undetermined), using a

QIAamp Blood Kit (Qiagen, Hilden, Germany). Using the oligo computer software package, version 4 (National Bioscience, Plymouth, MN, USA), PCR primers were designed to amplify the entire *TITF2* gene in two segments, avoiding the formation of primer dimers and hairpins as well as low values for the Gibbs' free energy of 3' pentamers. The primer sequences are 5'-CCG CGA CGA TCC CCT GAG-3' (1F), 5'-GCC GGG TAG GTG GAG AGG TC-3' (1R), 5'-GCT GGG CGG CAT CTA CAA GTT-3' (2F), and 5'-GCC TGC TCG GTC TTT TCC AC-3' (2R). The PCR reaction was performed using the Expand High-fidelity PCR System (Roche, Mannheim, Germany) in a 50 µl solution containing 12% dimethylsulfoxide. Forty-five PCR cycles were used, consisting of denaturation at 98 °C for 4 s, primer annealing at 55 °C for 30 s, and primer extension at 72 °C for 60 s. PCR products were electrophoresed in 1% SeaKem GTG agarose gel (FMC Bioproducts, Rockland, ME, USA) then purified with a GeneClean II kit (Bio101, La Jolla, CA, USA). Sequencing of the PCR products was carried out using a cycle sequencing method (Dye Terminator Cycle Sequencing Ready Reaction Kit; Perkin Elmer, Foster City, CA, USA) employing the same primers as those used for the PCR amplification. Subsequent analysis was performed on an ABI 377 Sequencer (Perkin Elmer). To study the allelic frequency of polyaniline-stretch lengths, genomic DNA from 101 normal individuals was amplified with the forward primer 5'-CTT CAA GCG CTC GGA CCT CTC-3' and the reverse primer 5'-ACG CCG CGG GGT AGT AGA CTG-3'. Differences in PCR-product lengths were analyzed on 2% Metaphor agarose gels (FMC Bioproducts). Polymorphisms of polyaniline-stretch lengths were confirmed by direct sequencing of the PCR products. Genomic DNA from family members of the patients with reduced polyaniline-stretch lengths was also analyzed by using the PCR direct sequencing method described above.

Functional analysis of *TTF-2*

Functional analysis was performed by transfecting cultured cell lines with *TITF2* expression plasmids and luciferase reporter plasmids transcriptionally directed by the human thyroglobulin promoter. To prepare the *TITF2* expression plasmids, entire *TITF2* genes, including the regions with variable polyaniline-stretch lengths, were amplified in single PCR reactions using the forward primer 1F and the reverse primer 2R. The PCR products were cleaned using a PCR purification kit (Qiagen) and ligated to a pcDNA3.1/V5/His-TOPO plasmid (Eukaryotic TOPO TA Cloning Kit; Invitrogen, Carlsbad, CA, USA). TOP10 One Shot chemically competent cells (Invitrogen) were transformed and colonies were analyzed for the presence of *TITF2* expression plasmids. The sequence of the *TITF2* gene in each clone was verified by sequencing, as described above. *TITF2* expression plasmids with mutations in

the forkhead domain, R72S, or disruption of the polyaniline tract by valine, (Ala)7(Val)(Ala)6, were also obtained after incorrect incorporation of nucleotides by the polymerase. The human thyroglobulin promoter (−340 bp to −21 bp), which includes a TTF-2 binding site (−147 bp to −136 bp), was amplified using the forward primer 5'-TTT GGT ACC TTT TCC CTC ACT GTG GCT TGA-3' and the reverse primer 5'-AAA GCT AGC GGA AGG AGG AGA AAC CAC TGC-3' and ligated to a luciferase reporter plasmid (pGL3-Basic Vector; Promega, Madison, WI, USA) after treatment with the restriction enzymes KpnI and NheI. The *TITF2* expression plasmids and the luciferase reporter plasmid, along with a pRL-CMV plasmid (Promega) that was used as an internal control, were co-transfected into the VMRC-LCD and G401 cell lines (both of which were obtained from the Human Science Research Resource Bank, Osaka, Japan), using liposome methods (Tfx-10 for VMRC-LCD and Tfx-20 for G401; Promega). Two days after transfection, the luciferase activity was measured with a luminometer (LUMAT LB 9507; EG&G Berthold, Bad Wildbad, Germany) using the Dual-Luciferase Reporter Assay System (Promega). Four independent transfection experiments were performed, each in triplicate, and the results were statistically analyzed by using paired Student's *t*-tests. Values of *P* < 0.01 were judged as significant.

Results

Sequencing of the entire coding region of the *TITF2* gene from 46 patients with thyroid dysgenesis revealed polymorphisms in the length of the polyaniline tract. Initially, the polyaniline tract was reported to consist of 19 residues (4), but the most frequent stretch length was 14 residues in 101 normal individuals (Table 1). The missing 5 residues from the 171th alanine to the 175th alanine are shown in Fig. 1. The longer stretch lengths with 16 alanine residues were found less frequently; the allelic frequency was 3% (6/202). In patients with thyroid dysgenesis, short polyaniline-stretch lengths of 11 and 12 residues were found to be heterozygous in two patients (one ectopy patient had (Ala)11/14 and one hypoplasia patient had (Ala)12/14) and also in one patient with (Ala)14/16. These

Table 1 Polymorphism of polyaniline-stretch length in the *TITF2* gene.

	Normal Individuals	Thyroid dysgenesis
11/14	0	1 (ectopy)
12/14	0	1 (hypoplasia)
14/14	96	43
14/16	4	1
16/16	1	0

441				450				459				468				477				486			
CGC	CGC	AAG	CGC	TTC	AAG	CGC	TCG	GAC	CTC	TCC	ACC	TAC	CCG	GCT	TAC	ATG	CAC	GAC					
R	R	K	R	F	K	R	S	D	L	S	T	Y	P	A	Y	M	H	D					
147				150				153				156				159				162			
495				504				513				522				531				540			
CGC	CGC	GCT	GCC	[GCA	GCC]	GCC	<u>GCT</u>	<u>GCC</u>	<u>GCA</u>	<u>GCC</u>	<u>GCC</u>	GCC	GCC	GCC	GCC	(GCC	GCC	GCC)					
A	A	A	A	[A	A]	A	<u>A</u>	<u>A</u>	<u>A</u>	<u>A</u>	<u>A</u>	A	A	A	A	(A	A	A)					
165				168				171				174				177				180			
549				558				567				576				585				594			
ATC	TTC	CCA	GGC	GCG	GTG	CCC	GCC	GCG	CGC	CCC	CCC	TAC	CCG	GGC	GCC	GTC	TAT	GCA					
I	F	P	G	A	V	P	A	A	R	P	P	Y	P	G	A	V	Y	A					
183				186				189				192				195				198			
603																							

Figure 1 Nucleotide sequence and its corresponding amino acid sequence for the TTF-2 gene around the polyalanine tract. 511–525del (AAAAA171–175del) is shown by underlining, 538–546del (AAA180–182del) is shown by '(', and 502–507del (AA168,169del) is shown by '['.]

reduced polyalanine residues of AAA180–182del and AA168,169del (Fig. 1) were not detected in 101 normal individuals. Other single nucleotide polymorphisms were detected in four locations with allelic frequencies from 10% (2/20) to <5% (<1/20), based on the sequences of 10 normal individuals (Table 2). These four single nucleotide polymorphisms did not result in changes of amino acids.

The effects of reduced polyalanine-tract length on the transcriptional activity of *TTF2* were studied by co-transfecting *TTF2* expression plasmids into cultured cell lines with a luciferase reporter plasmid transcriptionally directed by the human thyroglobulin promoter. A TTF-1-expressing lung cell line, VMRC-LCD, showed increased expression of luciferase by TTF-2, but a TTF-1-non-expressing kidney cell line, G401, did not show increased expression (data not shown). The degree of transcriptional stimulation by TTF-2 with different polyalanine-stretch lengths (11–14 residues) was not statistically different in the VMRC-LCD cells (Fig. 2). TTF-2 with a disrupted polyalanine tract, (Ala)7(Val)

(Ala)6, and a mutation in the forkhead domain, R72S, showed reduced stimulation of luciferase expression.

Discussion

Direct sequencing of the entire coding region of *TTF2* revealed a highly polymorphic polyalanine tract as well as four single nucleotide polymorphisms which did not alter the amino acid residues. The polymorphism of the polyalanine tract was reported previously, the polyalanine-stretch length being from 12 to 17 residues (12). In the 101 normal Japanese subjects, only two alleles with polyalanine-stretch lengths of 14 and 16 residues were found. Reduced polyalanine-tract length was found only in patients with thyroid dysgenesis, 11 residues being found in a patient with a sublingual ectopic thyroid gland, and 12 residues being found in a patient with thyroid hypoplasia. Alteration of polyalanine-stretch lengths has also been found in a homeobox-containing gene, *HOX D13*, consisting of a polyalanine tract with 15 residues (13, 14). In patients with the autosomal dominant disease synpolydactyly, elongated polyalanine tracts of 22–25 residues were reported.

A computer program that predicts protein secondary structure (nnPredict-UCSF; www.cmpharm.ucsf.edu/nomi/nnpredict.html) indicated that the polyalanine tract of TTF-2 constitutes an α -helical region C-terminal to the forkhead domain (A Hishinuma, unpublished observations). In several transcription factors which repress the transcription of target genes, alanine-rich

Table 2 Single nucleotide polymorphisms in the *TTF2* gene.

Nucleotide	Amino acid	Allelic frequency	
		Normal	Dysplasia
387C → T	L129L	0/20	2/92
519A → C	A173A	0/20	1/92
723C → T	P241P	2/20	5/92
834T → C	S278S	1/20	3/92

Figure 2 Luciferase reporter assay with different TTF-2 constructs. VMRC-LCD cells were transfected by TTF-2 expression plasmids and luciferase reporter plasmid directed by the human thyroglobulin promoter, as well as a pRL-CMV plasmid as an internal control. The luciferase activity was measured by the Dual-Luciferase Reporter Assay system. The relative intensities of the luciferase activities are shown. Four experiments (three determinations each time) were performed. *, $P < 0.01$ vs (Ala)14/14.

regions, which form α -helical regions and are responsible for the transcriptional repression, were identified (15–17). However, these transcriptional effector domains mediate both repression and activation, depending on the cell background (17). Activator or repressor regions of these transcription factors are adjacent or overlapping. For example, an alanine-rich region (residues 139–212) of *Drosophila* EVE-skipped is responsible for transcriptional activation, while the overlapping region (residues 139–227) mediates transcriptional repression (17).

TTF-2 has a dual function in the development of the thyroid gland (2). In the mouse, TTF-2 shows transient expression during the migration of thyroid precursor cells from the invagination of the pharyngeal endoderm to the final destination in front of the trachea. During this period, TTF-2 represses transcriptional activation of the thyroglobulin and thyroperoxidase promoters by TTF-1 and PAX8, respectively. Subsequently, TTF-2 expression is turned off; in adult thyroid tissue, however, TTF-2 expression is restored. In the adult thyroid, TTF-2 functions as a transcriptional activator of thyroglobulin (18) and thyroperoxidase (19, 20).

We performed functional analysis of TTF-2 with reduced polyalanine tracts by co-transfecting *TTF2* expression plasmids and luciferase reporter plasmids directed by the human thyroglobulin promoter. We found that TTF-2 activated luciferase expression in cells expressing the *TTF1* gene. The *TTF2* expression plasmid with a mutation (R72S) in the forkhead domain caused reduced expression of the reporter. The transcriptional function of TTF-2 with a missense mutation (A65V) in the forkhead domain was also abolished in patients with thyroid dysgenesis, cleft palate, and choanal atresia (11). However, no difference in the degree of luciferase expression by *TTF2* expression plasmids with polyalanine-stretch lengths

varying from 11 to 14 residues was found, though disruption of the polyalanine tract by valine, (Ala)7(Val)(Ala)6, did reduce transcriptional activation. Therefore, we have concluded that it is unlikely that polymorphism of the polyalanine tract is responsible for thyroid dysgenesis.

Acknowledgements

The authors wish to thank N Tamura and K Tabei for their technical assistance. This work was partially supported by a grant from the Japanese Ministry of Education, Science, Sports, and Culture (to A Hishinuma and T Ieiri).

References

- 1 Damante G & Di Lauro R. Thyroid-specific gene expression. *Biochimica et Biophysica Acta* 1994 **1218** 255–266.
- 2 Zannini M, Avantiaggiato V, Biffali E, Arnone MI, Sato K, Pischetola M *et al.* TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. *EMBO Journal* 1997 **16** 3185–3197.
- 3 De Felice M, Ovitt C, Biffali E, Rodriguez-Mallon A, Arra C, Anastassiadis K *et al.* A mouse model for hereditary thyroid dysgenesis and cleft palate. *Nature Genetics* 1998 **19** 395–398.
- 4 Chadwick BP, Obermayr F & Frischauf A-M. FKHL15, a new human member of the forkhead gene family located on chromosome 9q22. *Genomics* 1997 **41** 390–396.
- 5 Abramowicz MJ, Puprez L, Parma J, Vassart G & Heinrichs C. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. *Journal of Clinical Investigation* 1997 **99** 3018–3024.
- 6 Biebermann H, Schoeneberg T, Krude H, Schultz G, Gudermann T & Grueters A. Mutations of the human thyrotropin receptor gene causing thyroid hypoplasia and persistent congenital hypothyroidism. *Journal of Clinical Endocrinology and Metabolism* 1997 **82** 3471–3480.

- 7 Gagne N, Parma J, Deal C, Vassart G & Van Vliet G. Apparent congenital athyreosis consisting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? *Journal of Clinical Endocrinology and Metabolism* 1998 **83** 1771–1775.
- 8 Macchia PE, Lapi P, Krude H, Pirro MT, Missero C, Chiovato L *et al.* PAX8 mutations associated with congenital hypothyroidism caused by thyroid agenesis. *Nature Genetics* 1998 **19** 83–86.
- 9 Devriendt K, Vanhole C, Matthijs G & de Zegher F. Deletion of thyroid transcription factor-1 gene in an infant with neonatal thyroid dysfunction and respiratory failure. *New England Journal of Medicine* 1998 **338** 1317–1318.
- 10 Iwatani N, Mabe H, Devriendt K, Kodama M & Miike T. Deletion of NKX2-1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. *Journal of Pediatrics* 2000 **137** 272–276.
- 11 Clifton-Bligh RJ, Wentworth JM, Heinz P, Crisp MS, John R, Lazarus JH *et al.* Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. *Nature Genetics* 1998 **19** 399–401.
- 12 Macchia PE, Mattei M-G, Lapi P, Fenzi G & Di Lauro R. Cloning, chromosomal localization and identification of polymorphisms in the human thyroid transcription factor 2 gene (TTF-2). *Biochimie* 1999 **81** 433–440.
- 13 Muragaki Y, Mundlos S, Upton J & Olsen BR. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. *Science* 1996 **272** 548–551.
- 14 Akarsu AN, Stoilov I, Yilmaz E, Sayli BS & Sarfarazi M. Genomic structure of HOXD13 gene: a nine polyalanine duplication causes synpolydactyly in two unrelated families. *Human Molecular Genetics* 1996 **5** 945–952.
- 15 Licht JD, Grossel MJ, Figge J & Hansen UM. Drosophila Krueppel protein is a transcriptional repressor. *Nature* 1990 **346** 76–79.
- 16 Han K & Manley JL. Functional domains of the Drosophila Engrailed protein. *EMBO Journal* 1993 **12** 2723–2733.
- 17 Licht JD, Hanna-Rose W, Reddy JC, English MA, Ro M, Grossel M *et al.* Mapping and mutagenesis of the amino-terminal transcriptional repression domain of the Drosophila Krueppel protein. *Molecular and Cellular Biology* 1994 **14** 4057–4066.
- 18 Sinclair A, Lonigro R, Civitareale D, Ghibelli L & Di Lauro R. The tissue-specific expression of the thyroglobulin gene requires interaction between thyroid-specific and ubiquitous factors. *European Journal of Biochemistry* 1990 **193** 311–318.
- 19 Francis-Lang H, Price M, Polycarpou-Schwarz M & Di Lauro R. Cell-type-specific expression of the rat thyroperoxidase promoter indicates common mechanisms for thyroid-specific gene expression. *Molecular and Cellular Biology* 1992 **12** 576–588.
- 20 Aza-Blanc P, Di Lauro R & Santisteban P. Identification of a cis-regulatory element and a thyroid-specific nuclear factor mediating the hormonal regulation of rat thyroid peroxidase promoter activity. *Molecular Endocrinology* 1993 **7** 1297–1306.

Received 2 May 2001

Accepted 15 June 2001